MedTrace Logo

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT02985333 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.

Conditions

  • Relapse/Refractory Multiple Myeloma

Interventions

DRUG

Paclitaxel

Paclitaxel 170 mg/m(2) IV over 3 h d1

DRUG

Cyclophosphamide

Cyclophosphamide 200mgmg/m(2) IV d1,3,5

DRUG

Dexamethasone

Dexamethasone 20mg iv d1-4

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • yue lu, MD. · hematological oncology department

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985333 on ClinicalTrials.gov